Ctrl

K

Tesamorelin

Class
Hypothalamic-pituitary axis modulators
Subclass
Growth hormone-releasing hormone analogs
Substance name
Tesamorelin
Brand names
Egrifta Sv®
Common formulations
Powder and diluent for injection after reconstitution
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Avoid use. Evidence of fetal harm in humans. US FDA pregnancy category: X.
•
During pregnancy, visceral adipose tissue increases due to normal metabolic and hormonal changes; modifying this change with this drug offers no known benefit and may result in fetal harm.
•
If pregnancy occurs, discontinue therapy.
•
If this drug is used during pregnancy, or the patient becomes pregnant while on this drug, advise the patient of the potential harm to the fetus.
Breastfeeding
Little information available on breastfeeding safety.
•
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
↑ serum IGF-1, arthralgia, injection site reactions
Common 1-10%
•
Allergic reactions, generalized pruritus, skin flushing, skin rash, skin erythema, carpal tunnel syndrome, hypertension, ↑ HbA1c, ↑ serum CK, muscle strain, muscular rigidity, peripheral edema, peripheral neuropathy, chest pain, depression, epigastric abdominal pain, generalized pruritus, hypoesthesia, indigestion, insomnia, joint pain, joint swelling, limb pain, muscle spasms, musculoskeletal pain, myalgia, nausea, night sweats, pain, palpitations, paresthesia, skin flushing, skin rash, vomiting, urticaria
Unknown frequency
•
Abnormal oral glucose tolerance test, diabetes mellitus
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource